N/A
Completed N=300
Cefpodoxime vs Ciprofloxacin for Acute Cystitis
Source: ClinicalTrials.gov NCT00194532 ↗Enrolled (actual)
300
Serious AEs
0.0%
Results posted
Apr 2011
Primary outcomePrimary: Clinical Cure — 140; 123; 10; 27 participants
Summary
Urinary tract infection (UTI) is a very common problem in young healthy women, afflicting approximately one-half of women by their late 20s. One of the most common antibiotics used to treat UTIs is ciprofloxacin, usually for a total of three days. However, increasing resistance to this antibiotic has raised concerns about its overuse for cystitis and generated interest in alternative agents. An alternative antibiotic which is approved for use in UTIs is cefpodoxime. However, there are few studies evaluating the efficacy and tolerance of this compound when given in a 3-day regimen as is commonly used for treatment of UTI. The major purpose of this study is to assess the efficacy and tolerance of a 3-day regimen of cefpodoxime versus ciprofloxacin for treatment of acute uncomplicated cystitis.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Clinical Cure |
140; 123; 10; 27 | — |
| SECONDARY Microbiologic Cure |
123; 104; 5; 25 | — |
Eligibility Criteria
Inclusion Criteria
- Nonpregnant females in good general health with symptoms of acute cystitis
Exclusion Criteria
- Pregnant, lactating, or not regularly contracepting: known anatomic abnormalities of the urinary tract; use of prophylactic antibiotics; history of allergy or intolerance to any of the study drugs; recent (>2 weeks)exposure to an oral or parenteral antimicrobial; or history of UTI in the previous 1 month
Data sourced from ClinicalTrials.gov (NCT00194532). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.